Opinion|Videos|January 5, 2026
Real-World Tolerability and Safety Results for Axatilimab in cGVHD
Author(s)Leyla O. Shune, MD
Leyla O. Shune, MD, discusses an expanded access program in the United States that administered axatilimab to patients with chronic graft-versus-host disease. Specifically, she highlights the tolerability of axatilimab in the real-world setting.
Advertisement
Episodes in this series
Leyla O. Shune, MD, discusses an expanded access program in the United States that administered axatilimab to patients with chronic graft-versus-host disease. Specifically, she highlights the tolerability of axatilimab in the real-world setting. She compares the real-world results with the safety and tolerability outcomes observed in the AGAVE-201 (NCT04710576) trial, which supported the FDA approval of axatilimab for cGVHD.
Advertisement
Related to this article
Financial strain often eases after allogeneic bone marrow transplant, but persistent hardship worsens quality of life, highlighting the need for ongoing support.
Advertisement
Advertisement
Trending on Targeted Onc
1
HT-001 Trial Ended Early, Phase 3 Planned for EGFR Inhibitor Rash Management
2
Zanubrutinib Plus Rituximab Receives FDA Priority Review in Frontline MCL
3
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
4
Enfortumab Vedotin/Pembrolizumab Cost Effective in Bladder Cancer
5